Horizon Therapeutics Public Limited Company

BMV:HZNP N Stock Report

Market Cap: Mex$486.6b

Horizon Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Tim Walbert

Chief executive officer

US$20.1m

Total compensation

CEO salary percentage6.4%
CEO tenure15.3yrs
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure9.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tim Walbert's remuneration changed compared to Horizon Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

US$438m

Mar 31 2023n/an/a

US$372m

Dec 31 2022US$20mUS$1m

US$521m

Sep 30 2022n/an/a

US$574m

Jun 30 2022n/an/a

US$765m

Mar 31 2022n/an/a

US$862m

Dec 31 2021US$21mUS$1m

US$534m

Sep 30 2021n/an/a

US$552m

Jun 30 2021n/an/a

US$518m

Mar 31 2021n/an/a

US$280m

Dec 31 2020US$22mUS$1m

US$390m

Sep 30 2020n/an/a

US$792m

Jun 30 2020n/an/a

US$517m

Mar 31 2020n/an/a

US$592m

Dec 31 2019US$14mUS$1m

US$573m

Sep 30 2019n/an/a

US$82m

Jun 30 2019n/an/a

US$97m

Mar 31 2019n/an/a

US$77m

Dec 31 2018US$17mUS$1m

-US$38m

Sep 30 2018n/an/a

-US$178m

Jun 30 2018n/an/a

-US$275m

Mar 31 2018n/an/a

-US$460m

Dec 31 2017US$2mUS$1m

-US$350m

Sep 30 2017n/an/a

-US$495m

Jun 30 2017n/an/a

-US$437m

Mar 31 2017n/an/a

-US$212m

Dec 31 2016US$2mUS$950k

-US$166m

Compensation vs Market: Tim's total compensation ($USD20.10M) is above average for companies of similar size in the MX market ($USD5.70M).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.


CEO

Tim Walbert (56 yo)

15.3yrs

Tenure

US$20,103,869

Compensation

Mr. Timothy P. Walbert, also known as Tim, serves as an Independent Director at Mirum Pharmaceuticals, Inc. from April 05, 2023. He is an Independent Director of Century Therapeutics, Inc. since September...


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Walbert
Chairman15.3yrsUS$20.10mno data
Aaron Cox
Executive VP of Finance & CFO1.4yrsUS$7.17m0%
MX$ 0
Sean Clayton
Executive VP & General Counsel1.7yrsUS$10.87m0%
MX$ 0
Andy Pasternak
Executive VP & Chief Strategy Officer3.9yrsUS$6.75m0%
MX$ 0
Elizabeth Thompson
Executive Vice President of Research & Development2.6yrsUS$8.48m0%
MX$ 0
Patrick McIlvenny
Senior VP & Chief Accounting Officerless than a yearno data0%
MX$ 0
Tina Ventura
Senior VP & Chief Investor Relations Officerno datano datano data
Geoffrey Curtis
Executive VP of Corporate Affairs & Chief Communications Officer7.8yrsno datano data
Keli Walbert
Executive VP & Chief Marketing Officerless than a yearno datano data
Jane Gonnerman
Senior VP of Corporate Development & Chief of Staff2yrsno datano data
Irina Konstantinovsky
Executive VP6.1yrsUS$2.31mno data
Jeffrey Sherman
Executive VP & Chief Medical Officerno dataUS$5.86m0%
MX$ 0

2.3yrs

Average Tenure

48yo

Average Age

Experienced Management: HZNP N's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Timothy Walbert
Chairman15.3yrsUS$20.10mno data
Michael Grey
Lead Independent Director12.1yrsUS$551.24k0%
MX$ 0
William Daniel
Independent Director9.1yrsUS$522.49k0%
MX$ 0
Jeff Himawan
Independent Director16.3yrsUS$504.36k0%
MX$ 0
Gino Santini
Independent Director11.6yrsUS$494.99k0%
MX$ 0
H. Watkins
Independent Director9.5yrsUS$506.24k0%
MX$ 0
James Shannon
Independent Director6.2yrsUS$510.61k0%
MX$ 0
Susan Mahony
Independent Director4.2yrsUS$514.36k0%
MX$ 0
Pascale Witz
Independent Director6.2yrsUS$496.24k0%
MX$ 0

9.5yrs

Average Tenure

66yo

Average Age

Experienced Board: HZNP N's board of directors are considered experienced (9.5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/09 00:37
End of Day Share Price 2023/10/05 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Horizon Therapeutics Public Limited Company is covered by 24 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Donald EllisAvondale Partners
Gary NachmanBMO Capital Markets Equity Research
Jason Matthew GerberryBofA Global Research